Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A.
Total diagnosed and treated prevalent population of Hemophilia A in the 7MM was assessed to be 38,212 in 2017. The total prevalent population of Hemophilia A in the 7MM expected to rise by 2030, during the study period [2017–2030].
Among the European 5 countries, the United Kingdom had the highest prevalent population of Hemophilia A, followed by France and Italy while the lowest prevalent population of Hemophilia A was recorded in Spain.
According to DelveInsight's analysis, severe cases of Hemophilia A are more prominent in comparison to mild and moderate cases.
Key players in Haemophilia A market include Biomarin Pharmaceutical, Novo Nordisk, Sanofi, Pfizer, Catalyst Biosciences, OPKO Biologics, Spark Therapeutics, Sangamo therapeutics and others.
Some of the key emerging therapies in Haemophilia A market include Valoctocogene Roxaparvovec (BMN 270), Fitusiran, BIVV001, Marstacimab, Marzeptacog alfa, SB-525, SPK-8011.
For more details visit: https://www.delveinsight.com/report-store/hemophilia-a2030-market